ENTEROMEDICS INC FILES (8-K) Disclosing Change in Directors or Principal Officers

Edgar Glimpses |

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On June 23, 2014, the Board of Directors (the "Board") of EnteroMedics Inc. (the "Company") approved a special, one-time cash bonus for all employees of the Company in recognition of the vote by the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee (the "Panel") of the U.S. Food and Drug Administration regarding the safety, efficacy and benefit/risk ratio of the Company's Maestro Rechargeable System that occurred at the Panel's meeting on June 17, 2014.

Each employee, including the officers of the Company, will receive a cash bonus equal to 10\% of such employee's current, annual base salary. The cash bonus shall be pro-rated for any employee who was employed by the Company for fewer than 180 days as of June 17, 2014.



Additionally, as a result of the Panel's positive vote, and after consideration of a peer group compensation study conducted by Pearl Meyer & Partners ("Pearl Meyer") on behalf of the Company, the Board approved increases to the base annual salary of its officers, effective as of July 1, 2014. The Board adopted the salary increases based upon the recommendations of Pearl Meyer in order to align the compensation of the Company's officers with that of their peers in comparable companies. The following table sets forth the increase to the annual base salary for each of the Company's named executive officers and their new annual base salary as of July 1, 2014.

Annual Base Salary as of Name Position Salary Increase July 1, 2014 Mark Knudson Chairman, President, Chief $ 35,500 $ 389,552 Executive Officer Greg Lea Senior Vice President, Chief $ 27,500 $ 322,507 Financial Officer, Chief Operating Officer Adrianus Donders Senior Vice President of Research $ 13,000 $ 276,742 and Advanced Development Katherine Tweden Vice President, Clinical and $ 13,000 $ 277,258 Regulatory

--------------------------------------------------------------------------------

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
WWRSY GOLIATH GOLD MNG UNSP/ADR n/a n/a n/a 0

Comments

Emerging Growth

MGX Minerals Inc.

MGX Minerals is a diversified Canadian mining company listed on the Canadian Securities Exchange. MGX is engaged in the acquisition and development of industrial mineral deposits in western Canada that…

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…